中低收入国家COPD病例发现与自我管理行动计划的实施效果研究:GECo研究方案
GECo研究在尼泊尔、秘鲁和乌干达三个中低收入国家开展,旨在评估COPD病例发现问卷联合或不联合呼气峰流速的诊断准确性,并检验由社区健康工作者支持的COPD自我管理行动计划在急性加重管理中的有效性、成本效果和实施可行性。研究包括诊断准确性研究(GECo1)和实效性-实施性混合随机试验(GECo2),主要终点为12个月时圣乔治呼吸问卷评分。
要点
- GECo研究在中低收入国家评估COPD病例发现问卷的诊断准确性。
- GECo2试验检验社区健康工作者支持的自我管理行动计划的有效性。
- 主要终点为12个月时圣乔治呼吸问卷评分。
核心结论
- 研究旨在为中低收入国家COPD诊断和管理的实用模型提供证据。
研究设计与样本
- GECo1为诊断准确性研究,随机选取三个站点最多10500名40岁及以上成人,比较问卷联合或不联合呼气峰流速与肺量计检查的诊断性能。
- GECo2为实效性-实施性混合随机试验,目标入组240名中重度COPD患者,干预组接受COPD教育、促进自我管理行动计划和社区健康工作者每月访视,对照组接受COPD教育和标准治疗。
关键数值与推荐
- GECo1将报告ROC曲线下面积、灵敏度和特异度。
- GECo2主要终点为12个月时的圣乔治呼吸问卷评分,每3个月测量一次EQ-5D和SGRQ,持续1年。
- 还将计算基于SF-36第二版的 quality-adjusted life years(QALYs),并评估行动计划的接受度和可行性。
临床怎么用
- 研究结果可为中低收入国家采用实用模型进行COPD诊断和管理提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the end result of a susceptible individual being exposed to sufficiently deleterious environmental stimuli. More than 90% of COPD-related deaths occur in low- and middle-income countries (LMICs). LMICs face unique challenges in managing COPD; for example, deficient primary care systems present challenges for proper diagnosis and management. Formal diagnosis of COPD requires quality-assured spirometry, which is often limited to urban health centres. Similarly, standard treatment options for COPD remain limited where few providers are trained to manage COPD. The Global Excellence in COPD Outcomes (GECo) studies aim to assess the performance of a COPD case-finding questionnaire with and without peak expiratory flow (PEF) to diagnose COPD, and inform the effectiveness and implementation of COPD self-management Action Plans in LMIC settings. The ultimate goal is to develop simple, low-cost models of care that can be implemented in LMICs. This study will be carried out in Nepal, Peru and Uganda, three distinct LMIC settings. METHODS/DESIGN: We aim to assess the diagnostic accuracy of a simple questionnaire with and without PEF to case-find COPD (GECo1), and examine the effectiveness, cost-effectiveness and implementation of a community-health-worker-supported self-management Action Plan strategy for managing exacerbations of COPD (GECo2). To achieve the first aim, we will enrol a randomly selected sample of up to 10,500 adults aged ≥ 40 years across our three sites, with the goal to enrol 240 participants with moderate-to-severe COPD in to GECo2. We will apply two case-finding questionnaires (Lung Function Questionnaire and CAPTURE) with and without PEF and compare performance against spirometry. We will report ROC areas, sensitivity and specificity. Individuals who are identified as having COPD grades B-D will be invited to enrol in an effectiveness-implementation hybrid randomised trial of a multi-faceted COPD self-management Action Plan intervention delivered by CHWs. The intervention group will receive (1) COPD education, (2) facilitated-self management Action Plans for COPD exacerbations and (3) monthly visits by community health workers. The control group will receive COPD education and standard of care treatment provided by local health providers. Beginning at baseline, we will measure quality of life with the EuroQol-5D (EQ-5D) and St. George's Respiratory Questionnaire (SGRQ) every 3 months over a period of 1 year. The primary endpoint is SGRQ at 12 months. Quality-adjusted life years (QALYs) using the Short-Form 36 version 2 will also be calculated. We will additionally assess the acceptability and feasibility of implementing COPD Action Plans in each setting among providers and individuals with COPD. DISCUSSION: This study should provide evidence to inform the use of pragmatic models of COPD diagnosis and management in LMIC settings. TRIAL REGISTRATION: NCT03359915 (GECo1). Registered on 2 December 2017 and NCT03365713 (GECo2). Registered on 7 December 2017. Trial acronym: Global Excellence in COPD Outcomes (GECo1; GECo2).
引用
- Siddharthan T, Pollard SL, Quaderi SA, et al. Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECo) study protocol. Trials. 2018. PMID: 30340648. doi:10.1186/s13063-018-2909-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。